Pharma

Your Article Summary

See Latest Articles

Active Biotech Completes Patient Enrollment to TASQ Clinical Phase II study
Active Biotech, 06/09/09

Active Biotech announced that patient enrollment to the Phase II clinical trial for TASQ, a novel compound for the treatment of prostate cancer, is completed after enrollment of 200 patients into the study, according to the clinical protocol. The study is a 2:1 randomized, placebo-controlled, double-blind Phase II study of 1 mg/day TASQ versus placebo. The study encompasses symptom-free patients with metastatic, hormone-resistant, prostate cancer.

Today in Biotechnology...keeping you current

Receive free subspecialty "5-minute updates" via email

Position statement of the Portuguese Society of Nephrology on the clinical use of biotechnological drugs in renal patients
Portuguese Journal of Nephrology and Hypertension, 10/12/09

Orally Disintegrating Tablets: The Effect of Recent FDA Guidance on ODT Technologies and Applications
Pharmaceutical Technology, 10/14/09

Cardiac Cell Repair Therapy: A Clinical Perspective
Mayo Clinic Proceedings, 10/12/09

See All of Biotechnology

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
Clinical Cancer Research, 10/19/09

A Randomized Trial of Doxycycline for Mansonella perstans Infection
New England Journal of Medicine, 10/08/09

Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention
Trials, 10/28/09

See All of Drug Trials